Ferring to Present New Data on SI-6603 for Lumbar Disc Herniation at ASPN 2024

Ferring Pharmaceuticals and Seikagaku Corporation recently revealed two significant data analyses at the American Society of Pain and Neuroscience (ASPN) 2024 Annual Meeting in Miami, FL. These analyses pertained to SI-6603, an investigational therapy designed to alleviate radicular leg pain caused by lumbar disc herniation (LDH). The meeting is set to occur from July 11-24, 2024.

The presentations covered two critical aspects: an evaluation of early treatment response to SI-6603 and an analysis of healthcare resource utilization (HRU) and costs related to LDH surgeries. These presentations were based on data from completed clinical trials and provide valuable insights into the potential benefits and economic impact of the therapy.

The first presentation, identified as Poster #44, was titled "Early Response of SI-6603 (condoliase) for Lumbar Disc Herniation Associated With Radicular Leg Pain." Dr. Timothy R. Deer, a Clinical Professor of Anaesthesiology at West Virginia University School of Medicine and President & CEO of The Spine and Nerve Centers of the Virginias, delivered this analysis. The findings focused on the early response to SI-6603 from the United States Phase 3 Discovery 6603 clinical trial.

The second poster, denoted as Poster #171, addressed healthcare resource utilization and costs associated with lumbar disc herniation surgery in the United States. Dr. Kinsuk Chauhan, a Senior Manager of Real World Evidence and Health Economics Outcomes Research at Ferring Pharmaceuticals, presented this analysis. It explored the economic implications for patients undergoing surgical procedures for LDH.

Lumbar disc herniation is a prevalent condition affecting approximately 9 million adults annually in the U.S. This condition occurs when the nucleus pulposus, the gel-like core of the intervertebral disc, protrudes through the annulus fibrosus, the outer membrane, typically due to aging, wear and tear, or sudden injury. This displacement often compresses the spinal nerve, resulting in significant pain.

SI-6603, containing the active ingredient condoliase, is an experimental therapy aimed at treating radicular leg pain associated with lumbar disc herniation. It is administered via a single intradiscal injection. Developed by Seikagaku Corporation, SI-6603 received marketing approval in Japan from the Japanese Ministry of Health, Labour and Welfare in March 2018. Since August 1, 2018, it has been sold in Japan under the brand name HERNICORE® 1.25 units for intradiscal injection through Seikagaku Corporation's sales partner, Kaken Pharmaceutical Co., Ltd.

In August 2016, Seikagaku and Ferring Pharmaceuticals entered into a licensing agreement for SI-6603. Ferring aims to commercialize the product in the United States and has obtained rights to develop, register, and market SI-6603 globally, except in Japan.

Ferring Pharmaceuticals is a privately-owned, research-driven biopharmaceutical group dedicated to improving lives through innovative treatments. In the United States, Ferring is a leader in reproductive medicine and maternal health, as well as in gastroenterology and orthopedics. The company is also pioneering treatments in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Established in 1950 and headquartered in Saint-Prex, Switzerland, Ferring employs over 7,000 people worldwide and markets its products in more than 100 countries. Ferring USA operates out of Parsippany, New Jersey, with a workforce of over 900 employees.

These recent presentations at the ASPN Annual Meeting underscore Ferring and Seikagaku's commitment to advancing the treatment of lumbar disc herniation and improving patient outcomes through innovative therapies.